CO5680461A2 - Productos farmaceuticos que comprenden bisfosfonatos - Google Patents
Productos farmaceuticos que comprenden bisfosfonatosInfo
- Publication number
- CO5680461A2 CO5680461A2 CO06027690A CO06027690A CO5680461A2 CO 5680461 A2 CO5680461 A2 CO 5680461A2 CO 06027690 A CO06027690 A CO 06027690A CO 06027690 A CO06027690 A CO 06027690A CO 5680461 A2 CO5680461 A2 CO 5680461A2
- Authority
- CO
- Colombia
- Prior art keywords
- product according
- package
- organic
- base
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50440203P | 2003-09-18 | 2003-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5680461A2 true CO5680461A2 (es) | 2006-09-29 |
Family
ID=34312464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06027690A CO5680461A2 (es) | 2003-09-18 | 2006-03-21 | Productos farmaceuticos que comprenden bisfosfonatos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7932241B2 (OSRAM) |
| EP (1) | EP1663314A2 (OSRAM) |
| JP (1) | JP4802096B2 (OSRAM) |
| KR (1) | KR101015718B1 (OSRAM) |
| CN (1) | CN1852739A (OSRAM) |
| AR (1) | AR045670A1 (OSRAM) |
| AU (1) | AU2004271731B2 (OSRAM) |
| BR (1) | BRPI0414562A (OSRAM) |
| CA (1) | CA2536206C (OSRAM) |
| CO (1) | CO5680461A2 (OSRAM) |
| EC (1) | ECSP066419A (OSRAM) |
| IL (1) | IL173766A (OSRAM) |
| IS (1) | IS8351A (OSRAM) |
| MA (1) | MA28078A1 (OSRAM) |
| MY (1) | MY141763A (OSRAM) |
| NO (1) | NO20061682L (OSRAM) |
| NZ (1) | NZ545343A (OSRAM) |
| PE (1) | PE20050468A1 (OSRAM) |
| RU (1) | RU2358739C2 (OSRAM) |
| TN (1) | TNSN06084A1 (OSRAM) |
| TW (1) | TWI345977B (OSRAM) |
| WO (1) | WO2005025551A2 (OSRAM) |
| ZA (1) | ZA200601209B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050119230A1 (en) * | 2003-09-18 | 2005-06-02 | Alexandra Glausch | Pharmaceutical products comprising bisphosphonated |
| MY141763A (en) | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| EP1923049A1 (en) * | 2006-11-17 | 2008-05-21 | Besins Healthcare | Pharmaceutical compositions comprising a bisphosphonate compound |
| US20080182822A1 (en) * | 2006-11-17 | 2008-07-31 | Besins Healthcare Sa | Liquid Pharmaceutical Compositions Comprising a Bisphosphonate Compound |
| EP2144613B1 (en) * | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| JP5607408B2 (ja) * | 2009-04-03 | 2014-10-15 | 帝人ファーマ株式会社 | アレンドロン酸含有注射剤 |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| PT2459176T (pt) | 2009-07-31 | 2017-12-11 | Gruenenthal Gmbh | Método de cristalização e biodisponibilidade |
| US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
| EP2363111A1 (en) | 2010-03-01 | 2011-09-07 | Combino Pharm, S.L. | Stable pharmaceutical composition comprising bisphosphonate |
| WO2011132826A1 (en) * | 2010-04-19 | 2011-10-27 | Snu R&Db Foundation | Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| EP2712611A1 (en) | 2012-09-27 | 2014-04-02 | B. Braun Melsungen AG | Stabilized aqueous compositions of neuromuscular blocking agents |
| RU2506085C1 (ru) * | 2013-01-30 | 2014-02-10 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Тетраэтил-2-(2,2,6,6-тетраметилпиперидин-4-иламино)-этилен-1,1-бисфосфонат, обладающий противоопухолевой активностью |
| CN104721132B (zh) * | 2013-12-21 | 2018-05-18 | 石药集团恩必普药业有限公司 | 一种唑来膦酸注射液及其制备方法 |
| US10098813B2 (en) * | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
| GB201505347D0 (en) * | 2015-03-27 | 2015-05-13 | Salupont Consulting Ltd | Sterilisation of s-nitrosothiols |
| CN105232451B (zh) * | 2015-09-27 | 2019-02-05 | 青岛斯蒂朗机电设备有限公司 | 一种含有唑来膦酸的注射用组合物 |
| BR112018016287A2 (en) | 2016-02-09 | 2018-12-18 | Sun Pharmaceutical Industries Ltd. | Infusion system, method for administering directly to a patient in need thereof a dose of an antineoplastic drug and infusion container |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| AU2018342135A1 (en) * | 2017-08-28 | 2020-04-16 | Asdera Llc | Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation |
| JP2020535235A (ja) | 2017-09-28 | 2020-12-03 | アスデラ エルエルシー | リン脂質の調節異常が関与する疾患および障害におけるシクロデキストリンの使用 |
| CN110161168B (zh) * | 2018-02-12 | 2022-12-20 | 四川科伦药物研究院有限公司 | 唑来膦酸及其杂质的高效液相色谱检测方法 |
| JP7704740B2 (ja) | 2019-09-16 | 2025-07-08 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌の方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10199052I1 (de) * | 1986-11-21 | 2002-01-10 | Novartis Ag | Neue substituierte Alkandiphosphonsaeuren |
| JP3672342B2 (ja) | 1994-09-26 | 2005-07-20 | アステラス製薬株式会社 | ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル |
| FR2740686B1 (fr) * | 1995-11-03 | 1998-01-16 | Sanofi Sa | Formulation pharmaceutique lyophilisee stable |
| GB0012209D0 (en) * | 2000-05-19 | 2000-07-12 | Novartis Ag | Organic compounds |
| US20040082545A1 (en) * | 2000-09-18 | 2004-04-29 | Handreck Gregory Paul | Diphosphonate solutions |
| RU2003134700A (ru) * | 2001-05-02 | 2005-03-20 | Сикор Инк. (Us) | Динатрий памидронат для инъекций |
| CA2347330C (en) * | 2001-05-10 | 2002-03-12 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| MY141763A (en) | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
-
2004
- 2004-09-15 MY MYPI20043727A patent/MY141763A/en unknown
- 2004-09-16 AR ARP040103333A patent/AR045670A1/es unknown
- 2004-09-16 PE PE2004000900A patent/PE20050468A1/es not_active Application Discontinuation
- 2004-09-17 KR KR1020067005455A patent/KR101015718B1/ko not_active Expired - Fee Related
- 2004-09-17 RU RU2006112596/15A patent/RU2358739C2/ru not_active IP Right Cessation
- 2004-09-17 WO PCT/EP2004/010470 patent/WO2005025551A2/en not_active Ceased
- 2004-09-17 CN CNA2004800269883A patent/CN1852739A/zh active Pending
- 2004-09-17 JP JP2006526598A patent/JP4802096B2/ja not_active Expired - Lifetime
- 2004-09-17 TW TW093128260A patent/TWI345977B/zh not_active IP Right Cessation
- 2004-09-17 CA CA2536206A patent/CA2536206C/en not_active Expired - Fee Related
- 2004-09-17 EP EP04765362A patent/EP1663314A2/en not_active Ceased
- 2004-09-17 AU AU2004271731A patent/AU2004271731B2/en not_active Ceased
- 2004-09-17 NZ NZ545343A patent/NZ545343A/en not_active IP Right Cessation
- 2004-09-17 US US10/570,339 patent/US7932241B2/en not_active Expired - Fee Related
- 2004-09-17 BR BRPI0414562-3A patent/BRPI0414562A/pt not_active Application Discontinuation
-
2006
- 2006-02-10 ZA ZA200601209A patent/ZA200601209B/en unknown
- 2006-02-16 IL IL173766A patent/IL173766A/en not_active IP Right Cessation
- 2006-03-13 EC EC2006006419A patent/ECSP066419A/es unknown
- 2006-03-13 IS IS8351A patent/IS8351A/is unknown
- 2006-03-17 TN TNP2006000084A patent/TNSN06084A1/en unknown
- 2006-03-21 CO CO06027690A patent/CO5680461A2/es unknown
- 2006-03-27 MA MA28895A patent/MA28078A1/fr unknown
- 2006-04-12 NO NO20061682A patent/NO20061682L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200522969A (en) | 2005-07-16 |
| NZ545343A (en) | 2010-08-27 |
| WO2005025551A2 (en) | 2005-03-24 |
| JP4802096B2 (ja) | 2011-10-26 |
| CA2536206C (en) | 2010-08-24 |
| AU2004271731A1 (en) | 2005-03-24 |
| CA2536206A1 (en) | 2005-03-24 |
| KR20060087568A (ko) | 2006-08-02 |
| TWI345977B (en) | 2011-08-01 |
| RU2006112596A (ru) | 2007-11-10 |
| KR101015718B1 (ko) | 2011-02-22 |
| IL173766A0 (en) | 2006-07-05 |
| PE20050468A1 (es) | 2005-10-03 |
| MA28078A1 (fr) | 2006-08-01 |
| BRPI0414562A (pt) | 2006-11-07 |
| ECSP066419A (es) | 2006-09-18 |
| JP2007505861A (ja) | 2007-03-15 |
| RU2358739C2 (ru) | 2009-06-20 |
| CN1852739A (zh) | 2006-10-25 |
| WO2005025551A3 (en) | 2006-01-12 |
| EP1663314A2 (en) | 2006-06-07 |
| MY141763A (en) | 2010-06-30 |
| AR045670A1 (es) | 2005-11-02 |
| ZA200601209B (en) | 2007-04-25 |
| IL173766A (en) | 2012-10-31 |
| NO20061682L (no) | 2006-06-14 |
| US7932241B2 (en) | 2011-04-26 |
| AU2004271731B2 (en) | 2008-07-24 |
| US20070015736A1 (en) | 2007-01-18 |
| TNSN06084A1 (en) | 2007-10-03 |
| IS8351A (is) | 2006-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5680461A2 (es) | Productos farmaceuticos que comprenden bisfosfonatos | |
| JP6913458B2 (ja) | 抗菌水 | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| AR046773A1 (es) | Formulaciones farmaceuticas de bisfosfonatos | |
| AR098013A2 (es) | UNA COMPOSICIÓN FARMACÉUTICA ACUOSA ESTÉRIL, LISTA PARA SU USO, ADECUADA PARA LA ADMINISTRACIÓN PARENTERAL, MEDIANTE INFUSIÓN PARA EL TRATAMIENTO DE CONDICIONES CARDÍACAS, ENVASADA EN UN RECIPIENTE SELLADO, Y QUE POSEE UN pH ENTRE 3,5 Y 6,5, Y MÉTODO PARA SU FABRICACIÓN | |
| ATE361110T1 (de) | Arzneiverabreichung und verpackung | |
| ES2530791T3 (es) | Formulación de ibandronato de altas dosis | |
| CO5200840A1 (es) | Combinacion de sustancias activas con clonidina | |
| PE20050488A1 (es) | Formas de administracion masticables, no comprimidas, dosificadas individualmente | |
| AR007649A1 (es) | Composicion de relleno para forma de dosis farmaceutica de gelatina blanda y forma de dosis farmaceutica que la comprende | |
| MX2019008489A (es) | Tratamiento que comprende la administracion oral o gastrica de edaravona. | |
| AR046254A1 (es) | Productos farmaceuticos estables | |
| JP6099810B2 (ja) | 注射液製剤及びその製造方法 | |
| CA2466770A1 (en) | Liquid pharmaceutical formulations of acetaminophen and an alkali metal 1-lactate salt | |
| ES2393675T3 (es) | Composición conservante para uso oftálmico | |
| ES478272A1 (es) | Un procedimiento para la preparacion de una solucion acuosa esteril y estable de cisplatina. | |
| ATE352287T1 (de) | Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen | |
| WO2009150278A1 (es) | Una composición farmacéutica de melfalano | |
| JPWO2019107569A1 (ja) | 眼科用製品 | |
| CL2013002362A1 (es) | Sistema de administración de seguridad de cefuroxima que comprende un frasco estéril perforable llenado con una cantidad medida de cefuroxima, un receptáculo que contiene 0,1 de solución salina isotónica estéril por mg, una o más jeringas de administración con terminal leer macho; y sistema de administración con cartucho con dos cámaras separadas | |
| PE20051000A1 (es) | 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metil propionico (cci-779)" | |
| JP2022166168A (ja) | 眼科組成物 | |
| JP4598484B2 (ja) | 塩酸リトドリン注射液製剤 | |
| DE60321227D1 (de) | Zytotoxische pharmazeutische zusammensetzung | |
| JP5607408B2 (ja) | アレンドロン酸含有注射剤 |